Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Adenocarcinoma; Breast cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.
- 23 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2017.